Traws Pharma Inc (TRAW) - Net Assets
Based on the latest financial reports, Traws Pharma Inc (TRAW) has net assets worth $-5.31 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.16 Million) and total liabilities ($13.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore TRAW asset base for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.31 Million |
| % of Total Assets | -65.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | -101.36% |
| 10-Year Change | -112.27% |
| Growth Volatility | 263.99 |
Traws Pharma Inc - Net Assets Trend (2011–2025)
This chart illustrates how Traws Pharma Inc's net assets have evolved over time, based on quarterly financial data. Check Traws Pharma Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Traws Pharma Inc (2011–2025)
The table below shows the annual net assets of Traws Pharma Inc from 2011 to 2025. For live valuation and market cap data, see TRAW market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-629.00K | +98.01% |
| 2024-12-31 | $-31.63 Million | -396.38% |
| 2023-12-31 | $10.67 Million | -62.30% |
| 2022-12-31 | $28.31 Million | -38.62% |
| 2021-12-31 | $46.12 Million | +646.88% |
| 2020-12-31 | $6.17 Million | -46.65% |
| 2019-12-31 | $11.57 Million | +114.85% |
| 2018-12-31 | $5.39 Million | +149.60% |
| 2017-12-31 | $-10.86 Million | -311.84% |
| 2016-12-31 | $5.13 Million | -52.70% |
| 2015-12-31 | $10.84 Million | -54.11% |
| 2014-12-31 | $23.62 Million | -70.80% |
| 2013-12-31 | $80.90 Million | +151.10% |
| 2012-12-31 | $-158.31 Million | -14.37% |
| 2011-12-31 | $-138.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Traws Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 50154300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $90.00K | % |
| Other Comprehensive Income | $6.00K | % |
| Other Components | $639.26 Million | % |
| Total Equity | $-629.00K | 100.00% |
Traws Pharma Inc Competitors by Market Cap
The table below lists competitors of Traws Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KESSELRUN RESOURCES LTD
F:CMG
|
$6.86 Million |
|
Pool Advista Indonesia Tbk
JK:POOL
|
$6.86 Million |
|
DB ENERGY S.A. ZY -10
F:0CJ
|
$6.87 Million |
|
Straits Inter Logistics Bhd
KLSE:0080
|
$6.87 Million |
|
Credit Intelligence Ltd
AU:CI1
|
$6.85 Million |
|
Apptech Corp
NASDAQ:APCX
|
$6.85 Million |
|
Seafarms Group Ltd
AU:SFG
|
$6.84 Million |
|
REFINED METALS CORP. O.N.
F:CWA0
|
$6.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Traws Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -31,630,000 to -629,000, a change of 31,001,000.
- Net income of 9,170,000 contributed positively to equity growth.
- Share repurchases of 2,404,000 reduced equity.
- New share issuances of 5,582,000 increased equity.
- Other comprehensive income increased equity by 48,000.
- Other factors increased equity by 18,605,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $9.17 Million | +1457.87% |
| Share Repurchases | $2.40 Million | -382.19% |
| Share Issuances | $5.58 Million | +887.44% |
| Other Comprehensive Income | $48.00K | +7.63% |
| Other Changes | $18.61 Million | +2957.87% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Traws Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-614594.62 | $0.45 | x |
| 2012-12-31 | $-702894.95 | $0.45 | x |
| 2013-12-31 | $426956.57 | $0.45 | x |
| 2014-12-31 | $59093.39 | $0.45 | x |
| 2015-12-31 | $24761.29 | $0.45 | x |
| 2016-12-31 | $5460.25 | $0.45 | x |
| 2017-12-31 | $-7306.88 | $0.45 | x |
| 2018-12-31 | $489.86 | $0.45 | x |
| 2019-12-31 | $301.74 | $0.45 | x |
| 2020-12-31 | $13.31 | $0.45 | x |
| 2021-12-31 | $68.50 | $0.45 | x |
| 2022-12-31 | $33.85 | $0.45 | x |
| 2023-12-31 | $12.71 | $0.45 | x |
| 2024-12-31 | $-20.37 | $0.45 | x |
| 2025-12-31 | $-0.08 | $0.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Traws Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 328.67%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-154.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -2038.60% | 0.33x | 0.00x | $-16.47 Million |
| 2012 | 0.00% | -73.32% | 0.55x | 0.00x | $-18.03 Million |
| 2013 | -80.66% | -1364.67% | 0.05x | 1.31x | $-72.90 Million |
| 2014 | -279.95% | -7960.25% | 0.02x | 2.08x | $-65.96 Million |
| 2015 | -239.55% | -209.31% | 0.49x | 2.34x | $-24.98 Million |
| 2016 | -457.69% | -354.62% | 0.24x | 5.41x | $-20.10 Million |
| 2017 | 0.00% | -3061.25% | 0.16x | 0.00x | $-22.92 Million |
| 2018 | -381.90% | -1675.33% | 0.07x | 3.33x | $-21.11 Million |
| 2019 | -185.79% | -985.02% | 0.09x | 2.05x | $-22.66 Million |
| 2020 | -407.40% | -10890.48% | 0.01x | 3.24x | $-25.77 Million |
| 2021 | -35.05% | -7151.77% | 0.00x | 1.20x | $-20.77 Million |
| 2022 | -66.99% | -8391.15% | 0.01x | 1.39x | $-21.79 Million |
| 2023 | -177.55% | -8384.07% | 0.01x | 2.13x | $-20.02 Million |
| 2024 | 0.00% | -24192.04% | 0.01x | 0.00x | $-51.51 Million |
| 2025 | 0.00% | 328.67% | 0.26x | 0.00x | $9.23 Million |
Industry Comparison
This section compares Traws Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Traws Pharma Inc (TRAW) | $-5.31 Million | 0.00% | N/A | $6.85 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more